Cytek Biosciences, Inc. — Director's Dealing 2021

Jul 28, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cytek Biosciences, Inc. (CTKB)
CIK: 0001831915
Period of Report: 2021-07-22

Reporting Person: Jiang Wenbin (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-07-22	Common Stock	C	2666600	—	Acquired	2666600	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-22	Series A Preferred Stock	$	C	2666600	Disposed		Common Stock (2666600)	Indirect

Footnotes

F1: Each share of Preferred Stock automatically converted on a one-for-one basis into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date.

F2: These securities are held by WYTJ LLC for which the Reporting Person is a Manager. The Reporting Person disclaims beneficial ownership of the shares held by WYTJ LLC except to the extent of his pecuniary interest therein, if any.